IKBKB and B-cell chronic lymphocytic leukemia: In contrast to other NFκB inhibitors (e.g., TPCA-1), SpiD3 spares healthy lymphocytes and attenuates NFκB activity in CLL cells, possibly through cross-linking both p65 and IKKβ (14), demonstrating a potential therapeutic window for SpiD3 in CLL.